A first-of-its-kind treatment has been approved for narcolepsy, a sleep disorder. But drugmakers hope the therapy could be used more broadly. Listen to “Babbage” https://t.co/93hbMWAYP9 ...

President Trump says he's nominating Dr. Heidi Overton to be his next FDA commissioner, elevating a longtime ally to lead the embattled agency. https://t.co/S0FnxxQYpU https://t.co/EanR4KDwm7 ...

Breaking news this morning from pharma giants Madna and Merc. The companies say that an experimental vaccine treatment shows promise in preventing melanoma from returning or spreading in high-risisk patients. The mRNA vaccine was tested on people who had already had surgery to remove melanoma.The companies have not published those findings yet. They described it as a firstofits-kind breakthrough. ...

Sam, I I say huge news because the market reaction has been huge. So in the pharmaceutical world, is this a really big breakthrough. Oh, hi, Dani.I think the best share price to look at is Merck because that's where you're getting no, let's say, dilution of the of of or or involvement of short covering that's probably going on in the Moderna share price move at the open. So that's giving us a 7%, 9% rise. Right.This is huge for Merck depending on the data. Remember the press release only says that they succ ...

“A few in the drug community are wondering whether this could be as big as the GLP medicines.” @chitnis_ introduces “The Intelligence” to orexins, a promising peptide class https://t.co/oJ5LbrUBGx ...

https://t.co/EY4SqxUHujNone (@None):Under the microscope this week: $LLY.Eli Lilly, maker of Mounjaro and Zepbound, became the first healthcare company to reach a $1T valuation in 2025.Tomorrow, $LLY lists on @Solana through Sunrise, issued by @Backpack Securities.Today, Solana goes under the microscope too. https://t.co/FSEnPwhH0k ...

The study will run into 2028, testing two low doses of Wegovy, and follows the company disclosing recently that uptake of the pill had been particularly strong for its lowest doses across self-paying patients. https://t.co/OOfVT4Rosc ...

Market Dynamics - Pharmaceutical enterprises constantly hunt for drugs to replace expiring blockbusters [1] Investment Risks - Pharmaceutical enterprises face expensive mistakes when acquiring assets hastily due to urgent pipeline demands [1]

Novo Nordisk is testing small doses of its blockbuster Wegovy pill in a new study that will help establish how low patients can go in their dose and still lose weight https://t.co/Q4VfHHSIRu ...

China is becoming Big Pharma’s go-to source for promising new drugs — and the expanding ties are alarming Washington https://t.co/zOpnmwUXgx ...